Bladder hyperthermia in the treatment of vesical papillomatosis.
D001414:Bacitracin / Q000627:therapeutic use; D002021:Buffers; D004338:Drug Combinations; D005500:Follow-Up Studies; D006417:Hematuria / Q000209:etiology / Q000628:therapy; D006358:Hot Temperature / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007970:Leukopenia / Q000209:etiology; D008722:Methods; D009355:Neomycin / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D010212:Papilloma / Q000188:drug therapy / Q000628:therapy*; D010710:Phosphates / Q000627:therapeutic use; D012601:Scopolamine / Q000627:therapeutic use; D012965:Sodium Chloride / Q000627:therapeutic use; D007507:Therapeutic Irrigation / Q000295:instrumentation; D013852:Thiotepa / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D014357:Trypsin / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000628:therapy*; D014555:Urination Disorders / Q000209:etiology
D002021:Buffers; D004338:Drug Combinations; D010710:Phosphates; D001414:Bacitracin; D012965:Sodium Chloride; D013852:Thiotepa; D012601:Scopolamine; D014357:Trypsin; D009355:Neomycin